Lacydyna

Lacidipine, the active ingredient in Lacydyna, is a dihydropyridine calcium channel blocker presented as a tablet for oral use. It works by relaxing vascular smooth muscle, thereby reducing systemic vascular resistance and lowering elevated blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Lacydyna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for healthcare providers across multiple markets. The company adheres to stringent quality standards and offers global logistics support to ensure timely delivery.

Lacydyna, a dihydropyridine calcium channel blocker, is indicated for conditions related to high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to achieve target levels in adult patients.

Lacidipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache often reported. - Flushing: transient warmth and redness of the skin. - Dizziness: light‑headed sensation, especially after standing. - Peripheral edema: swelling of ankles or feet. - Tachycardia: increased heart rate. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing faintness. - Myocardial infarction: rare occurrence of heart attack. - Angina: chest pain due to reduced coronary flow. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Arrhythmias: irregular heart rhythms.

Before prescribing Lacydyna, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive lowering. - Cardiovascular status: avoid in patients with unstable angina or recent myocardial infarction. - Liver function: assess hepatic impairment, as metabolism may be altered. - Drug interactions: review concomitant CYP3A4 inhibitors or inducers. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Lacidipine can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma concentrations. - Grapefruit juice: can markedly raise drug levels, leading to hypotension. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood pressure lowering may require dose adjustment. - Diuretics: combined use can increase risk of electrolyte disturbances. - Beta‑blockers: monitor for excessive bradycardia or AV block.